Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
24 results loaded, newest first. End of these results.
Stride reported first-quarter revenue of $639.4 million, up 3% year over year, while enrollment came in below expectations amid technology-platform issues affecting applications and new-student retention. The company forecast full-year revenue of $2.53 billion to $2.61 billion and adjusted operating income of $500 mill
Immunovant CEO Matthew Gline said the company expects to launch brepocitinib by the end of September, pending FDA action. The company also reported enrollment in a phase 3 cutaneous sarcoidosis study and outlined anticipated second-half data readouts.
For best results when printing this announcement, please click on link below: Strong ROI for AI Nearly 3X More Common When Companies Measure Growth Versus Efficiency Alone, Wharton-GBK Study Finds Fourth annual study finds 80% of enterprise leaders report positive AI returns, but only 28% see strong ROI, as workflow tr
On Thursday, Cytokinetics (NASDAQ: CYTK ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary Cytokinetics reported strong commercial momentum for Myc
Galaxy Digital (NASDAQ: GLXY ) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered APIs. For comprehensive financial data and transcripts, visit Access the full call at Summary Galaxy Digital reported a GAAP net loss of $85 mill
On Thursday, Chegg (NYSE: CHGG ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit Access the full call at Summary Chegg Incorporated exceeded expectations on revenue, adjusted
Reuters listed M&A bids and deals reported by 0930 GMT Tuesday, including BPCE’s 7% Sabadell stake purchase, Informa’s £2.24 billion bid for Clarion, and KKR’s $5.1 billion deal for Gen II Fund Services, plus other transactions.
Iovance Biotherapeutics (NASDAQ: IOVA ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. Access the full call
Oct 6 (Reuters) — Informa PLC: Informa Plc - Growth, Focus & International Expansion Informa - Announces Plans To Separate Taylor & Francis Informa - To Buy Clarion In £2.24 Billion Deal Informa - Identifies £50 Million Annual Run Rate Operating Synergies Informa - Acquisition Expected To Enhance Adjusted Diluted Eps I
Informa announced plans to separate its academic business, Taylor & Francis, in order to concentrate on its core B2B operations.
Britain's Informa plans to separate its academic business, Taylor & Francis, to focus on its core B2B business.
Informa announced plans to separate its Academic Markets business, which includes Taylor & Francis.
Immunocore Hldgs (NASDAQ: IMCR ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Immunocore H
Insmed (NASDAQ: INSM ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Insmed reported strong
Amylyx Pharma (NASDAQ: AMLX ) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is available at Summary Amylyx Pharma re
On Thursday, Roivant Sciences (NASDAQ: ROIV ) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Roivant Sciences reported a quiet
The specialist dermatology and oncology company said it achieved first revenues from skin+CELL direct-to-consumer sales and completed a strategic acquisition of Swiss skincare brand énielle. It also said it raised gross proceeds of £355,000 through unsecured convertible loan notes.
Worldsec Limited reported an unaudited net loss of US$490,000 for the six months ended 30 June 2026, versus a loss of US$97,000 a year earlier. The company also said it appointed Elemental Company Secretary Limited as company secretary in September 2026.
IonQ and SDT have formed a multi-year strategic partnership to bring advanced quantum computing and quantum networking to the Asia-Pacific region. The collaboration will see IonQ supply SDT with a Superion 256 quantum computer and a silicon-vacancy quantum memory module for deployment in South Korea.
Establishment Labs announced product line extensions of Mia and Preservé with new sizes and supporting tools at the 11th World Symposium on Ergonomic Implants in Istanbul. The company also presented new clinical and scientific data supporting Breast Tissue Preservation and its Minimally Invasive Platform.
Prenetics Global (NASDAQ: PRE ) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. The full earnings call is ava
On Thursday, Immunovant (NASDAQ: IMVT ) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. View the webcast at Summary Immunovant reported a quiet
Research Solutions said fiscal 2026 revenue was $48.3 million, down from $49.1 million in fiscal 2025. Platform subscription revenue rose 10% to $20.8 million, and the company said it booked about $800,000 in AI-related orders in Q4.
John Wiley & Sons said Q1 Research publishing revenue rose 12%, while Learning revenue fell 20%. The company reiterated full-year guidance for mid-single-digit organic revenue growth, adjusted EPS of $4.60 to $5.05 and free cash flow of $205 million.